Korea S.E.
18:00:00 2024-06-27 EDT
5-day change
1st Jan Change
4,800
KRW
-0.10%
-1.84%
-15.79%
Korea Arlico Pharm Co., Ltd. announced that it expects to receive KRW 2.82 billion in funding from IBK Securities Co., Ltd.
Korea Arlico Pharm Co., Ltd. (KOSDAQ:A260660) announced a private placement of 235,000 common shares at a price of KRW 12,000 for gross proceeds of KRW 2,820,000,000 on March 12, 2018. The transaction will involve participation from IBK Securities Co. Ltd. The transaction will be carried out through third party allotment method. The transaction has been approved by the board of directors of the company.
Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding
11-09
CI
Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding
11-07
CI
Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding from Hanyang Securities Co., Ltd., Investment Arm, NH Hedge Co., Ltd., SUSUNG ASSET MANAGEMENT Co., Ltd., Infinity Investment Advisory Co.,Ltd., and other investors
22-02-17
CI
Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from Hanyang Securities Co., Ltd., Investment Arm, NH Hedge Co., Ltd., SUSUNG ASSET MANAGEMENT Co., Ltd., Infinity Investment Advisory Co.,Ltd. and other investors
22-02-10
CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on October 6, 2021.
21-10-18
CI
Korea Arlico Pharm Co.,Ltd.'s Equity Buyback announced on October 6, 2021, has closed with 64,000 shares, representing 0.42% for KRW 496.14 million.
21-10-14
CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for 64,000 shares.
21-10-06
CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.
21-10-05
CI
An unknown buyer acquired 2.5% stake in Korea Arlico Pharm Co.,Ltd. from Hanggu Lee for KRW 3.5 billion.
20-07-28
CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on March 13, 2020.
20-03-24
CI
Korea Arlico Pharm Co.,Ltd.'s Equity Buyback announced on March 13, 2020, has closed with 102,400 shares, representing 1.07% for KRW 837.77 million.
20-03-22
CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for 102,040 shares.
20-03-13
CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.
20-03-12
CI
Korea Arlico Pharm Co.,Ltd.'s Equity Buyback announced on June 3, 2019, has expired.
19-12-01
CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on June 3, 2019.
19-09-02
CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares.
19-06-02
CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.
19-06-02
CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on August 20, 2018.
19-02-22
CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on August 20, 2018.
19-02-22
CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on August 20, 2018.
19-02-22
CI
Korea Arlico Pharm. Co., Ltd.’s Equity Buyback announced on August 20, 2018 has expired with 87,968 shares, representing 0.92% for KRW 1,076.43 million.
19-02-18
CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
18-08-20
CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.
18-08-19
CI
Korea Arlico Pharm Co., Ltd. announced that it has received KRW 2.82 billion in funding from IBK Securities Co., Ltd.
18-03-12
CI
Korea Arlico Pharm Co., Ltd. announced that it expects to receive KRW 2.82 billion in funding from IBK Securities Co., Ltd.
18-03-11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
KOREA ARLICO PHARM CO.,LTD. is a Korea-based company that mainly engaged in the manufacturing and sale of pharmaceuticals. The Company manufactures and sells circulation system drugs, digestion drugs, anti-inflammatory analgesic, other prescription drug for treating hypertension, hyperlipidemia, peptic ulcer, indigestion, osteoarthritis, pain, and dementia, among others. The Company distributes its products within the domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-15.79% 53.39M +19.97% 43.77B +30.16% 22.83B +20.25% 15.56B +18.70% 14.34B +54.14% 12.96B -0.05% 6.79B -11.72% 6.41B -8.87% 5.73B +14.65% 5.69B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
KOREA ARLICO PHARM CO.,LTD. 
